美国食品和药物管理局拒绝了一种新的糖尿病药物Zynquista, The FDA rejected a new diabetes drug, Zynquista, due to safety concerns, impacting Lexicon Pharmaceuticals' plans.

林业发展局拒绝Lexicon制药公司要求Zynquista(sotagliflozin)治疗患有1型糖尿病和慢性肾病的成年人的申请,指出担心该药物的风险大于其好处。 The FDA has rejected Lexicon Pharmaceuticals' application for Zynquista (sotagliflozin) to treat adults with type 1 diabetes and chronic kidney disease, citing concerns that the drug's risks outweigh its benefits. 这一决定是在咨询委员会投票反对批准后作出的。 This decision follows an advisory committee's vote against approval. Lexicon计划将重点放在输油管中的其他药物上,包括糖尿病神经病痛药物。 Lexicon plans to focus on other drugs in its pipeline, including one for diabetic neuropathic pain.